Literature DB >> 19140211

Silent myocardial ischemia is associated with altered plasma phospholipids.

Hailong Lin1, Jing Zhang, Peng Gao.   

Abstract

Timely and accurate confirmation of the occurrence of silent myocardial ischemia (SMI) is critical both for prevention and therapy management. Metabolomics assay may offer an alternative for SMI differentiation and altered biomolecule discovery in addition to traditional measures. In this study, plasma samples were obtained from 14 diagnosed SMI subjects and 25 healthy controls and analyzed by liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry in view of metabolomics. Obtained data were subjected to orthogonal signal correction partial least-squares discriminate analysis. Multi-variate statistic analysis indicated a clear separation between the two studied groups. Plasma concentration fluctuation of four kinds of phospholipids showed tight relationship with the occurrence of SMI, among which 1-linoleoylglycerophosphocholine (C18:2) was decreased statistically in SMI population (P=0.01). The plasma phospholipids' changes were before enzymatic alteration in SMI, which might be a useful complementary reference to facilitate SMI diagnosis. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19140211      PMCID: PMC6649157          DOI: 10.1002/jcla.20288

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  21 in total

Review 1.  Metabolic profiling as a tool for understanding mechanisms of toxicity.

Authors:  Christopher J Clarke; John N Haselden
Journal:  Toxicol Pathol       Date:  2008-01       Impact factor: 1.902

Review 2.  Metabolomics for phytomedicine research and drug development.

Authors:  Lie-Fen Shyur; Ning-Sun Yang
Journal:  Curr Opin Chem Biol       Date:  2008-02-21       Impact factor: 8.822

3.  Metabolomic identification of novel biomarkers of myocardial ischemia.

Authors:  Marc S Sabatine; Emerson Liu; David A Morrow; Eric Heller; Robert McCarroll; Roger Wiegand; Gabriel F Berriz; Frederick P Roth; Robert E Gerszten
Journal:  Circulation       Date:  2005-12-12       Impact factor: 29.690

4.  Severity of coronary artery calcification by electron beam computed tomography predicts silent myocardial ischemia.

Authors:  Z X He; T D Hedrick; C M Pratt; M S Verani; V Aquino; R Roberts; J J Mahmarian
Journal:  Circulation       Date:  2000-01-25       Impact factor: 29.690

Review 5.  Should silent ischemia be treated in asymptomatic individuals?

Authors:  P F Cohn
Journal:  Circulation       Date:  1990-09       Impact factor: 29.690

6.  Lysophosphatidylcholine activates p38 and p42/44 mitogen-activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulated chemotaxis.

Authors:  Q Jing; S M Xin; W B Zhang; P Wang; Y W Qin; G Pei
Journal:  Circ Res       Date:  2000-07-07       Impact factor: 17.367

7.  No effect of statin therapy on silent myocardial ischemia in patients with type 2 diabetes without manifest cardiovascular disease.

Authors:  Edith D Beishuizen; J Wouter Jukema; Jouke T Tamsma; Marcel A van de Ree; J Carel M van der Vijver; Hein Putter; Arie C Maan; A Edo Meinders; Menno V Huisman
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

8.  Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells.

Authors:  N Kume; M A Gimbrone
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

9.  Prognostic importance of silent ischemia during long-term follow-up of patients with coronary artery disease. A short review based on own experience and current literature.

Authors:  J Erikssen
Journal:  Herz       Date:  1987-12       Impact factor: 1.443

10.  Significance of silent myocardial ischemia during exercise testing in patients with coronary artery disease.

Authors:  D A Weiner; T J Ryan; C H McCabe; S Luk; B R Chaitman; L T Sheffield; F Tristani; L D Fisher
Journal:  Am J Cardiol       Date:  1987-04-01       Impact factor: 2.778

View more
  7 in total

Review 1.  Metabolomics: moving to the clinic.

Authors:  Anders Nordström; Rolf Lewensohn
Journal:  J Neuroimmune Pharmacol       Date:  2009-04-28       Impact factor: 4.147

2.  Biomarkers intersect with the exposome.

Authors:  Stephen M Rappaport
Journal:  Biomarkers       Date:  2012-06-07       Impact factor: 2.658

Review 3.  Metabolomics of oxidative stress in recent studies of endogenous and exogenously administered intermediate metabolites.

Authors:  Jia Liu; Lawrence Litt; Mark R Segal; Mark J S Kelly; Jeffrey G Pelton; Myungwon Kim
Journal:  Int J Mol Sci       Date:  2011-09-28       Impact factor: 5.923

4.  A Comparative Metabolomics Approach Reveals Early Biomarkers for Metabolic Response to Acute Myocardial Infarction.

Authors:  Sara E Ali; Mohamed A Farag; Paul Holvoet; Rasha S Hanafi; Mohamed Z Gad
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

5.  Metabolomic Signature of Coronary Artery Disease in Type 2 Diabetes Mellitus.

Authors:  Bernd Stratmann; Katrin Richter; Ruichao Wang; Zhonghao Yu; Tao Xu; Cornelia Prehn; Jerzy Adamski; Thomas Illig; Diethelm Tschoepe; Rui Wang-Sattler
Journal:  Int J Endocrinol       Date:  2017-03-02       Impact factor: 3.257

6.  Perturbations in cardiac metabolism in a human model of acute myocardial ischaemia.

Authors:  Sanoj Chacko; Mamas A Mamas; Magdi El-Omar; David Simon; Sohaib Haseeb; Farzin Fath-Ordoubadi; Bernard Clarke; Ludwig Neyses; Warwick B Dunn
Journal:  Metabolomics       Date:  2021-08-23       Impact factor: 4.290

7.  Plasma Metabolomics of Acute Coronary Syndrome Patients Based on Untargeted Liquid Chromatography-Mass Spectrometry.

Authors:  Wei Zhong; Qiaoting Deng; Xunwei Deng; Zhixiong Zhong; Jingyuan Hou
Journal:  Front Cardiovasc Med       Date:  2021-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.